Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity

Jeff A. Sosman, Peter C. Kohler, Jacquelyn Hank, Karen H. Moore, Robin Bechhofer, Barry Storer, Paul M. Sondel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

133 Scopus citations

Abstract

A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 × 106 U/m2/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (>50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity. [J Natl Cancer Inst 1988;80:60-63]

Original languageEnglish (US)
Pages (from-to)60-63
Number of pages4
JournalJournal of the National Cancer Institute
Volume80
Issue number1
DOIs
StatePublished - Mar 2 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity'. Together they form a unique fingerprint.

Cite this